1.54 USD
-0.05 (-3.14%)
1.54 USD
0 (0%)
We assign a fundamental rating of 4 out of 10 to AKBA. AKBA was compared to 531 industry peers in the Biotechnology industry. While AKBA is still in line with the averages on profitability rating, there are concerns on its financial health. AKBA has a decent growth rate and is not valued too expensively.
1. Profitability
1.1 Basic Checks
In the past year AKBA has reported negative net income.
In the past year AKBA had a positive cash flow from operations.
In the past 5 years AKBA always reported negative net income.
AKBA had a negative operating cash flow in each of the past 5 years.
1.2 Ratios
AKBA's Return On Assets of -4.37% is amongst the best of the industry. AKBA outperforms 86.36% of its industry peers.
With a decent Return On Equity value of -38.24%, AKBA is doing good in the industry, outperforming 71.59% of the companies in the same industry.
AKBA has a better Return On Invested Capital (6.90%) than 93.27% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -4.37% | ||
| ROE | -38.24% | ||
| ROIC | 6.9% |
ROA(3y)-26.46%
ROA(5y)-38.48%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
With an excellent Operating Margin value of 8.95%, AKBA belongs to the best of the industry, outperforming 91.03% of the companies in the same industry.
The Gross Margin of AKBA (82.52%) is better than 85.61% of its industry peers.
AKBA's Gross Margin has improved in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 8.95% | ||
| PM (TTM) | N/A | ||
| GM | 82.52% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y17.75%
GM growth 5Y4.73%
2. Health
2.1 Basic Checks
With a Return on Invested Capital (ROIC) below the Cost of Capital (WACC), AKBA is destroying value.
AKBA has more shares outstanding than it did 1 year ago.
The number of shares outstanding for AKBA has been increased compared to 5 years ago.
Compared to 1 year ago, AKBA has a worse debt to assets ratio.
2.2 Solvency
AKBA has an Altman-Z score of -4.45. This is a bad value and indicates that AKBA is not financially healthy and even has some risk of bankruptcy.
AKBA's Altman-Z score of -4.45 is on the low side compared to the rest of the industry. AKBA is outperformed by 60.75% of its industry peers.
The Debt to FCF ratio of AKBA is 5.97, which is a neutral value as it means it would take AKBA, 5.97 years of fcf income to pay off all of its debts.
With an excellent Debt to FCF ratio value of 5.97, AKBA belongs to the best of the industry, outperforming 91.03% of the companies in the same industry.
AKBA has a Debt/Equity ratio of 4.30. This is a high value indicating a heavy dependency on external financing.
Looking at the Debt to Equity ratio, with a value of 4.30, AKBA is doing worse than 82.24% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 4.3 | ||
| Debt/FCF | 5.97 | ||
| Altman-Z | -4.45 |
ROIC/WACC0.88
WACC7.87%
2.3 Liquidity
A Current Ratio of 1.94 indicates that AKBA should not have too much problems paying its short term obligations.
AKBA has a worse Current ratio (1.94) than 77.76% of its industry peers.
A Quick Ratio of 1.80 indicates that AKBA should not have too much problems paying its short term obligations.
Looking at the Quick ratio, with a value of 1.80, AKBA is doing worse than 77.38% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.94 | ||
| Quick Ratio | 1.8 |
3. Growth
3.1 Past
AKBA shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 69.57%, which is quite impressive.
Looking at the last year, AKBA shows a very strong growth in Revenue. The Revenue has grown by 32.49%.
The Revenue for AKBA have been decreasing by -13.72% on average. This is quite bad
EPS 1Y (TTM)69.57%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%100%
Revenue 1Y (TTM)32.49%
Revenue growth 3Y-8.88%
Revenue growth 5Y-13.72%
Sales Q2Q%57.01%
3.2 Future
Based on estimates for the next years, AKBA will show a very strong growth in Earnings Per Share. The EPS will grow by 26.23% on average per year.
Based on estimates for the next years, AKBA will show a very strong growth in Revenue. The Revenue will grow by 23.72% on average per year.
EPS Next Y113.6%
EPS Next 2Y54.73%
EPS Next 3Y44.79%
EPS Next 5Y26.23%
Revenue Next Year58.44%
Revenue Next 2Y39.29%
Revenue Next 3Y28.83%
Revenue Next 5Y23.72%
3.3 Evolution
The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings Ratio is negative for AKBA. In the last year negative earnings were reported.
The Price/Forward Earnings ratio is 11.84, which indicates a very decent valuation of AKBA.
AKBA's Price/Forward Earnings ratio is rather cheap when compared to the industry. AKBA is cheaper than 97.38% of the companies in the same industry.
AKBA is valuated cheaply when we compare the Price/Forward Earnings ratio to 23.69, which is the current average of the S&P500 Index.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | 11.84 |
4.2 Price Multiples
94.95% of the companies in the same industry are more expensive than AKBA, based on the Enterprise Value to EBITDA ratio.
Based on the Price/Free Cash Flow ratio, AKBA is valued cheaper than 97.20% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 12.7 | ||
| EV/EBITDA | 14.26 |
4.3 Compensation for Growth
The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
AKBA's earnings are expected to grow with 44.79% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y54.73%
EPS Next 3Y44.79%
5. Dividend
5.1 Amount
AKBA does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
1.54
-0.05 (-3.14%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners47.42%
Inst Owner Change13.83%
Ins Owners3.57%
Ins Owner Change1.5%
Market Cap408.67M
Revenue(TTM)225.07M
Net Income(TTM)-15.90M
Analysts87.27
Price Target5.51 (257.79%)
Short Float %14.13%
Short Ratio8.27
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)100%
Min EPS beat(2)100%
Max EPS beat(2)100%
EPS beat(4)3
Avg EPS beat(4)85.7%
Min EPS beat(4)-22.55%
Max EPS beat(4)165.36%
EPS beat(8)5
Avg EPS beat(8)49.92%
EPS beat(12)8
Avg EPS beat(12)29.94%
EPS beat(16)9
Avg EPS beat(16)25.61%
Revenue beat(2)1
Avg Revenue beat(2)14.3%
Min Revenue beat(2)-1.07%
Max Revenue beat(2)29.66%
Revenue beat(4)3
Avg Revenue beat(4)18.97%
Min Revenue beat(4)-1.07%
Max Revenue beat(4)29.66%
Revenue beat(8)3
Avg Revenue beat(8)1.71%
Revenue beat(12)4
Avg Revenue beat(12)-0.75%
Revenue beat(16)8
Avg Revenue beat(16)11.83%
PT rev (1m)-27.03%
PT rev (3m)-27.03%
EPS NQ rev (1m)-160%
EPS NQ rev (3m)46.43%
EPS NY rev (1m)1860%
EPS NY rev (3m)162.86%
Revenue NQ rev (1m)-10.53%
Revenue NQ rev (3m)3.84%
Revenue NY rev (1m)-0.65%
Revenue NY rev (3m)10.24%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | 11.84 | ||
| P/S | 1.82 | ||
| P/FCF | 12.7 | ||
| P/OCF | 12.61 | ||
| P/B | 9.83 | ||
| P/tB | N/A | ||
| EV/EBITDA | 14.26 |
EPS(TTM)-0.07
EYN/A
EPS(NY)0.13
Fwd EY8.44%
FCF(TTM)0.12
FCFY7.87%
OCF(TTM)0.12
OCFY7.93%
SpS0.85
BVpS0.16
TBVpS-0.07
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -4.37% | ||
| ROE | -38.24% | ||
| ROCE | 8.73% | ||
| ROIC | 6.9% | ||
| ROICexc | 24.74% | ||
| ROICexgc | 301.13% | ||
| OM | 8.95% | ||
| PM (TTM) | N/A | ||
| GM | 82.52% | ||
| FCFM | 14.3% |
ROA(3y)-26.46%
ROA(5y)-38.48%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y17.75%
GM growth 5Y4.73%
F-Score4
Asset Turnover0.62
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 4.3 | ||
| Debt/FCF | 5.97 | ||
| Debt/EBITDA | 5.88 | ||
| Cap/Depr | 2.17% | ||
| Cap/Sales | 0.1% | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 106.44% | ||
| Profit Quality | N/A | ||
| Current Ratio | 1.94 | ||
| Quick Ratio | 1.8 | ||
| Altman-Z | -4.45 |
F-Score4
WACC7.87%
ROIC/WACC0.88
Cap/Depr(3y)0.13%
Cap/Depr(5y)0.3%
Cap/Sales(3y)0.02%
Cap/Sales(5y)0.04%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)69.57%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%100%
EPS Next Y113.6%
EPS Next 2Y54.73%
EPS Next 3Y44.79%
EPS Next 5Y26.23%
Revenue 1Y (TTM)32.49%
Revenue growth 3Y-8.88%
Revenue growth 5Y-13.72%
Sales Q2Q%57.01%
Revenue Next Year58.44%
Revenue Next 2Y39.29%
Revenue Next 3Y28.83%
Revenue Next 5Y23.72%
EBIT growth 1Y162.89%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y142.47%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y142.77%
OCF growth 3YN/A
OCF growth 5YN/A
AKEBIA THERAPEUTICS INC / AKBA FAQ
What is the fundamental rating for AKBA stock?
ChartMill assigns a fundamental rating of 4 / 10 to AKBA.
Can you provide the valuation status for AKEBIA THERAPEUTICS INC?
ChartMill assigns a valuation rating of 6 / 10 to AKEBIA THERAPEUTICS INC (AKBA). This can be considered as Fairly Valued.
How profitable is AKEBIA THERAPEUTICS INC (AKBA) stock?
AKEBIA THERAPEUTICS INC (AKBA) has a profitability rating of 4 / 10.
Can you provide the financial health for AKBA stock?
The financial health rating of AKEBIA THERAPEUTICS INC (AKBA) is 3 / 10.